

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Sisram Medical Ltd**  
**復銳醫療科技有限公司\***  
*(Incorporated in Israel with limited liability)*  
**(Stock Code: 1696)**

**RESIGNATION OF DIRECTOR AND  
APPOINTMENT OF DIRECTOR**

**RESIGNATION OF DIRECTOR**

The board of directors (the “**Board**”) of Sisram Medical Ltd (the “**Company**”) hereby announced that Ms. Yang YANG has tendered her resignation from the position of non-executive director of the Company with effect from 20 August 2019 due to her decision to pursue her personal development.

Ms. Yang YANG has confirmed that she has no disagreement with the Board and there are no matters relating to her resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

The Board hereby expresses its gratitude to Ms. Yang YANG for her valuable contribution to the Company during her term of office.

**APPOINTMENT OF DIRECTOR**

The Board also announced that, with effect from 20 August 2019, Ms. Kun DAI (“**Ms. DAI**”) has been appointed as a non-executive director of the Company.

Ms. DAI, aged 42, has been the assistant to president and the general manager of the human resources of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* (上海復星醫藥(集團)股份有限公司) (a company listed both on The Stock Exchange of Hong Kong Limited (stock code: 2196) and the Shanghai Stock Exchange (stock code: 600196)) since March 2018. She has been appointed as a non-executive director of Sinopharm Group Co. Ltd.\* (國藥控股股份有限公司) (a company listed on The Stock Exchange of Hong Kong Limited (stock code: 1099)) since June 2019. Previously, she worked as a business representative for China International Intellectech Co., Ltd.\* (中國國際技術智力合作有限公司) from July 2000 to November 2001. From November 2001 to February 2012, she worked successively as the assistant to the vice president of the human resources, the human resources specialist, the human resources executive and the associate director of the human resources of Beijing Novartis Pharma Ltd.\* (北京諾華製藥有限公司). From March 2012 to March 2018, she worked successively as the head of human resources of both the Greater China region and Korean area of the OTC drug division of Novartis\* (諾華集團), the head of the recruitment center of the Greater China region and the head of human resources of the enterprise services of Novartis China\* (諾華集團(中國)). Ms. DAI obtained a bachelor degree in Arts from China University of Political Science and Law in the PRC in June 2000.

Save as disclosed above, Ms. DAI did not hold any directorship in listed public companies in the three years preceding the date of this announcement, nor does she has any relationship with any other director or senior management of the Company, or substantial or controlling shareholders of the Company.

As at the date of this announcement, Ms. DAI does not have any interest in the shares or underlying shares of the Company and its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Ms. DAI has entered into a letter of appointment with the Company for a period commencing from 20 August 2019 and ending on 30 August 2020 in accordance with the articles of association of the Company. Pursuant to the articles of association of the Company, Ms. DAI will hold office as non-executive director of the Company until the forthcoming annual general meeting of the Company and will then stand for re-election at that meeting. Ms. DAI will not receive any emolument from the Company for acting as non-executive director of the Company.

Save as disclosed above, there is no other matter that needs to be brought to the attention of the Shareholders in connection with Ms. DAI's appointment and there is no other information that should be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board would like to extend their warm welcome to Ms. DAI in joining the Board.

On Behalf of the Board  
**Sisram Medical Ltd**  
復銳醫療科技有限公司\*  
**Yi LIU**  
*Chairman*

Hong Kong, 20 August 2019

*As at the date of this announcement, the board of directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as executive directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Kun DAI as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.*

\* for identification purpose only